{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:16:26Z","timestamp":1778091386134,"version":"3.51.4"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,6]]},"DOI":"10.7759\/cureus.108373","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:44:46Z","timestamp":1778089486000},"source":"Crossref","is-referenced-by-count":0,"title":["Targeted Metabolic Therapy in Cancer: A Comprehensive Metabolic Treatment Strategy"],"prefix":"10.7759","author":[{"given":"Yahia","family":"Anane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray F","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024, 74:229-63. 10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan D","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011, 144:646-74. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg O","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956, 123:309-14. 10.1126\/science.123.3191.309","journal-title":"Science"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt480","article-title":"Cancer as a metabolic disease: implications for novel therapeutics","volume":"35","author":"Seyfried TN","year":"2014","unstructured":"Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014, 35:515-27. 10.1093\/carcin\/bgt480","journal-title":"Carcinogenesis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova NN","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016, 23:27-47. 10.1016\/j.cmet.2015.12.006","journal-title":"Cell Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer","volume":"6","author":"Roxburgh CS","year":"2010","unstructured":"Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010, 6:149-63. 10.2217\/fon.09.136","journal-title":"Future Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007981","article-title":"The association between diabetes\/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis","volume":"96","author":"Chen S","year":"2017","unstructured":"Chen S, Tao M, Zhao L, Zhang X. The association between diabetes\/hyperglycemia and the prognosis of cervical cancer patients: a systematic review and meta-analysis. Medicine (Baltimore). 2017, 96:e7981. 10.1097\/MD.0000000000007981","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and cancer biology","volume":"168","author":"Vander Heiden MG","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017, 168:657-69. 10.1016\/j.cell.2016.12.039","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-092910-154237","article-title":"Aerobic glycolysis: meeting the metabolic requirements of cell proliferation","volume":"27","author":"Lunt SY","year":"2011","unstructured":"Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011, 27:441-64. 10.1146\/annurev-cellbio-092910-154237","journal-title":"Annu Rev Cell Dev Biol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3124","article-title":"Metabolic pathways promoting cancer cell survival and growth","volume":"17","author":"Boroughs LK","year":"2015","unstructured":"Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015, 17:351-9. 10.1038\/ncb3124","journal-title":"Nat Cell Biol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69741","article-title":"Targeting lactate metabolism for cancer therapeutics","volume":"123","author":"Doherty JR","year":"2013","unstructured":"Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest. 2013, 123:3685-92. 10.1172\/JCI69741","journal-title":"J Clin Invest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc882","article-title":"Molecular imaging of cancer with positron emission tomography","volume":"2","author":"Gambhir SS","year":"2002","unstructured":"Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002, 2:683-93. 10.1038\/nrc882","journal-title":"Nat Rev Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02847-w","article-title":"Prognostic role of glycolysis for cancer outcome: evidence from 86 studies","volume":"145","author":"Yu M","year":"2019","unstructured":"Yu M, Chen S, Hong W, et al.. Prognostic role of glycolysis for cancer outcome: evidence from 86 studies. J Cancer Res Clin Oncol. 2019, 145:967-99. 10.1007\/s00432-019-02847-w","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-152","article-title":"Tumor glycolysis as a target for cancer therapy: progress and prospects","volume":"12","author":"Ganapathy-Kanniappan S","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind JF. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013, 12:152. 10.1186\/1476-4598-12-152","journal-title":"Mol Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman BJ","year":"2016","unstructured":"Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016, 16:619-34. 10.1038\/nrc.2016.71","journal-title":"Nat Rev Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.358","article-title":"Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer","volume":"29","author":"DeBerardinis RJ","year":"2010","unstructured":"DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010, 29:313-24. 10.1038\/onc.2009.358","journal-title":"Oncogene"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69600","article-title":"Glutamine and cancer: cell biology, physiology, and clinical opportunities","volume":"123","author":"Hensley CT","year":"2013","unstructured":"Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013, 123:3678-84. 10.1172\/JCI69600","journal-title":"J Clin Invest"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-bioeng-071516-044546","article-title":"Glutaminolysis: a hallmark of cancer metabolism","volume":"19","author":"Yang L","year":"2017","unstructured":"Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017, 19:163-94. 10.1146\/annurev-bioeng-071516-044546","journal-title":"Annu Rev Biomed Eng"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.01.005","article-title":"Glutamine metabolism in cancer: understanding the heterogeneity","volume":"3","author":"Cluntun AA","year":"2017","unstructured":"Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017, 3:169-80. 10.1016\/j.trecan.2017.01.005","journal-title":"Trends Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75836","article-title":"Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis","volume":"125","author":"Xiang Y","year":"2015","unstructured":"Xiang Y, Stine ZE, Xia J, et al.. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest. 2015, 125:2293-306. 10.1172\/JCI75836","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/35025220","article-title":"Angiogenesis in cancer and other diseases","volume":"407","author":"Carmeliet P","year":"2000","unstructured":"Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000, 407:249-57. 10.1038\/35025220","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02317-1","article-title":"HIF-1 and tumor progression: pathophysiology and therapeutics","volume":"8","author":"Semenza GL","year":"2002","unstructured":"Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002, 8:62-7. 10.1016\/S1471-4914(02)02317-1","journal-title":"Trends Mol Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith B","year":"2011","unstructured":"Keith B, Johnson RS, Simon MC. HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011, 12:9-22. 10.1038\/nrc3183","journal-title":"Nat Rev Cancer"},{"key":"ref24","article-title":"Overexpression of hypoxia-inducible factor 1\u03b1 in common human cancers and their metastases","volume":"59","author":"Zhong H","year":"1999","unstructured":"Zhong H, De Marzo AM, Laughner E, et al.. Overexpression of hypoxia-inducible factor 1\u03b1 in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5.","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: a review of programmed cell death","volume":"35","author":"Elmore S","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007, 35:495-516. 10.1080\/01926230701320337","journal-title":"Toxicol Pathol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Cory S","year":"2002","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002, 2:647-56. 10.1038\/nrc883","journal-title":"Nat Rev Cancer"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2147","article-title":"p53 in health and disease","volume":"8","author":"Vousden KH","year":"2007","unstructured":"Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007, 8:275-83. 10.1038\/nrm2147","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge AR","year":"2015","unstructured":"Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015, 22:1071-80. 10.1038\/cdd.2015.50","journal-title":"Cell Death Differ"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan D","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022, 12:31-46. 10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang CH","year":"2015","unstructured":"Chang CH, Qiu J, O'Sullivan D, et al.. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015, 162:1229-41. 10.1016\/j.cell.2015.08.016","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell-derived lactic acid on human T cells","volume":"109","author":"Fischer K","year":"2007","unstructured":"Fischer K, Hoffmann P, Voelkl S, et al.. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007, 109:3812-9. 10.1182\/blood-2006-07-035972","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian SL","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015, 27:450-61. 10.1016\/j.ccell.2015.03.001","journal-title":"Cancer Cell"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman JA","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9:550-62. 10.1038\/nrc2664","journal-title":"Nat Rev Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton RA","year":"2017","unstructured":"Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017, 168:960-76. 10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan TL","year":"2008","unstructured":"Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008, 27:5497-510. 10.1038\/onc.2008.245","journal-title":"Oncogene"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2536","article-title":"Insulin and insulin-like growth factor signalling in neoplasia","volume":"8","author":"Pollak M","year":"2008","unstructured":"Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008, 8:915-28. 10.1038\/nrc2536","journal-title":"Nat Rev Cancer"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan T","year":"2017","unstructured":"Zhan T, Rindtorff N, Boutros M. Wnt signaling in cancer. Oncogene. 2017, 36:1461-73. 10.1038\/onc.2016.304","journal-title":"Oncogene"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers H","year":"2012","unstructured":"Clevers H, Nusse R. Wnt\/\u03b2-catenin signaling and disease. Cell. 2012, 149:1192-205. 10.1016\/j.cell.2012.05.012","journal-title":"Cell"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger S","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015, 523:231-5. 10.1038\/nature14404","journal-title":"Nature"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle E","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017, 23:1124-34. 10.1038\/nm.4409","journal-title":"Nat Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean M","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005, 5:275-84. 10.1038\/nrc1590","journal-title":"Nat Rev Cancer"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao S","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, et al.. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006, 444:756-60. 10.1038\/nature05236","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2014.07.001","article-title":"Cancer stem cells, cancer cell plasticity and radiation therapy","volume":"31","author":"Vlashi E","year":"2015","unstructured":"Vlashi E, Pajonk F. Cancer stem cells, cancer cell plasticity and radiation therapy. Semin Cancer Biol. 2015, 31:28-35. 10.1016\/j.semcancer.2014.07.001","journal-title":"Semin Cancer Biol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi LT","year":"2018","unstructured":"Phi LT, Sari IN, Yang YG, et al.. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018, 2018:5416923. 10.1155\/2018\/5416923","journal-title":"Stem Cells Int"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert AW","year":"2017","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017, 168:670-91. 10.1016\/j.cell.2016.11.037","journal-title":"Cell"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle M","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011, 20:576-90. 10.1016\/j.ccr.2011.09.009","journal-title":"Cancer Cell"},{"key":"ref47","article-title":"Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium","volume":"63","author":"Glinsky VV","year":"2003","unstructured":"Glinsky VV, Glinsky GV, Glinskii OV, et al.. Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium. Cancer Res. 2003, 63:3805-11.","journal-title":"Cancer Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2796","article-title":"Acidity generated by the tumor microenvironment drives local invasion","volume":"73","author":"Estrella V","year":"2013","unstructured":"Estrella V, Chen T, Lloyd M, et al.. Acidity generated by the tumor microenvironment drives local invasion. Cancer Res. 2013, 73:1524-35. 10.1158\/0008-5472.CAN-12-2796","journal-title":"Cancer Res"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9506-4","article-title":"Extracellular acidity, a \"reappreciated\" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy","volume":"33","author":"Peppicelli S","year":"2014","unstructured":"Peppicelli S, Bianchini F, Calorini L. Extracellular acidity, a \"reappreciated\" trait of tumor environment driving malignancy: perspectives in diagnosis and therapy. Cancer Metastasis Rev. 2014, 33:823-32. 10.1007\/s10555-014-9506-4","journal-title":"Cancer Metastasis Rev"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani A","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008, 454:436-44. 10.1038\/nature07205","journal-title":"Nature"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov SI","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010, 140:883-99. 10.1016\/j.cell.2010.01.025","journal-title":"Cell"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the pre-metastatic niche","volume":"30","author":"Liu Y","year":"2016","unstructured":"Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer Cell. 2016, 30:668-81. 10.1016\/j.ccell.2016.09.011","journal-title":"Cancer Cell"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and cancer: a consensus report","volume":"33","author":"Giovannucci E","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, et al.. Diabetes and cancer: a consensus report. Diabetes Care. 2010, 33:1674-85. 10.2337\/dc10-0666","journal-title":"Diabetes Care"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110352","article-title":"Paraneoplastic thrombocytosis in ovarian cancer","volume":"366","author":"Stone RL","year":"2012","unstructured":"Stone RL, Nick AM, McNeish IA, et al.. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012, 366:610-8. 10.1056\/NEJMoa1110352","journal-title":"N Engl J Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard I","year":"2009","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M, et al.. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009, 69:5383-91. 10.1158\/0008-5472.CAN-08-3845","journal-title":"Cancer Res"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman D","year":"2014","unstructured":"Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014, 14:342-57. 10.1038\/nrc3691","journal-title":"Nat Rev Cancer"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/nu8030163","article-title":"Micronutrients in oncological intervention","volume":"8","author":"Gr\u00f6ber U","year":"2016","unstructured":"Gr\u00f6ber U, Holzhauer P, Kisters K, Holick MF, Adamietz IA. Micronutrients in oncological intervention. Nutrients. 2016, 8:163. 10.3390\/nu8030163","journal-title":"Nutrients"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2008.07.007","article-title":"Melatonin, sleep disturbance and cancer risk","volume":"13","author":"Blask DE","year":"2009","unstructured":"Blask DE. Melatonin, sleep disturbance and cancer risk. Sleep Med Rev. 2009, 13:257-64. 10.1016\/j.smrv.2008.07.007","journal-title":"Sleep Med Rev"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9495-3","article-title":"Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation","volume":"33","author":"Klement RJ","year":"2014","unstructured":"Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R's through dietary manipulation. Cancer Metastasis Rev. 2014, 33:217-29. 10.1007\/s10555-014-9495-3","journal-title":"Cancer Metastasis Rev"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2014.08.002","article-title":"Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism","volume":"2","author":"Allen BG","year":"2014","unstructured":"Allen BG, Bhatia SK, Anderson CM, et al.. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014, 2:963-70. 10.1016\/j.redox.2014.08.002","journal-title":"Redox Biol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-8-54","article-title":"Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial","volume":"8","author":"Schmidt M","year":"2011","unstructured":"Schmidt M, Pfetzer N, Schwab M, Strauss I, K\u00e4mmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011, 8:54. 10.1186\/1743-7075-8-54","journal-title":"Nutr Metab (Lond)"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.12.008","article-title":"Fasting: molecular mechanisms and clinical applications","volume":"19","author":"Longo VD","year":"2014","unstructured":"Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014, 19:181-92. 10.1016\/j.cmet.2013.12.008","journal-title":"Cell Metab"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708100105","article-title":"Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy","volume":"105","author":"Raffaghello L","year":"2008","unstructured":"Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, Longo VD. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008, 105:8215-20. 10.1073\/pnas.0708100105","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1663-5","article-title":"The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study","volume":"15","author":"de Groot S","year":"2015","unstructured":"de Groot S, Vreeswijk MP, Welters MJ, et al.. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015, 15:652. 10.1186\/s12885-015-1663-5","journal-title":"BMC Cancer"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2014.04.014","article-title":"Prolonged fasting reduces IGF-1\/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression","volume":"14","author":"Cheng CW","year":"2014","unstructured":"Cheng CW, Adams GB, Perin L, et al.. Prolonged fasting reduces IGF-1\/PKA to promote hematopoietic-stem-cell-based regeneration and reverse immunosuppression. Cell Stem Cell. 2014, 14:810-23. 10.1016\/j.stem.2014.04.014","journal-title":"Cell Stem Cell"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105207","article-title":"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang M","year":"2021","unstructured":"Tang M, Hu X, Wang Y, et al.. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021, 163:105207. 10.1016\/j.phrs.2020.105207","journal-title":"Pharmacol Res"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12543","article-title":"Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway","volume":"52","author":"Zhang P","year":"2019","unstructured":"Zhang P, Zhang Y, Liu K, et al.. Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway. Cell Prolif. 2019, 52:e12543. 10.1111\/cpr.12543","journal-title":"Cell Prolif"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-262675","article-title":"The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells","volume":"116","author":"Sharmeen S","year":"2010","unstructured":"Sharmeen S, Skrtic M, Sukhai MA, et al.. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010, 116:3593-603. 10.1182\/blood-2010-01-262675","journal-title":"Blood"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30158-6","article-title":"Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways","volume":"8","author":"Dogra N","year":"2018","unstructured":"Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018, 8:11926. 10.1038\/s41598-018-30158-6","journal-title":"Sci Rep"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-07-2159","article-title":"Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells","volume":"6","author":"Doudican N","year":"2008","unstructured":"Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 2008, 6:1308-15. 10.1158\/1541-7786.MCR-07-2159","journal-title":"Mol Cancer Res"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.4158\/EP10390.CR","article-title":"Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma","volume":"17","author":"Dobrosotskaya IY","year":"2011","unstructured":"Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract. 2011, 17:e59-62. 10.4158\/EP10390.CR","journal-title":"Endocr Pract"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1021\/cb600362d","article-title":"Inhibition of angiogenesis by the antifungal drug itraconazole","volume":"2","author":"Chong CR","year":"2007","unstructured":"Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr, Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol. 2007, 2:263-70. 10.1021\/cb600362d","journal-title":"ACS Chem Biol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim J","year":"2010","unstructured":"Kim J, Tang JY, Gong R, et al.. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010, 17:388-99. 10.1016\/j.ccr.2010.02.027","journal-title":"Cancer Cell"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-314","article-title":"Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer","volume":"18","author":"Antonarakis ES","year":"2013","unstructured":"Antonarakis ES, Heath EI, Smith DC, et al.. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist. 2013, 18:163-73. 10.1634\/theoncologist.2012-314","journal-title":"Oncologist"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2310","article-title":"Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells","volume":"67","author":"Dowling RJ","year":"2007","unstructured":"Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67:10804-12. 10.1158\/0008-5472.CAN-07-2310","journal-title":"Cancer Res"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in cancer treatment and prevention","volume":"66","author":"Morales DR","year":"2015","unstructured":"Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015, 66:17-29. 10.1146\/annurev-med-062613-093128","journal-title":"Annu Rev Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1177\/1535370213488483","article-title":"Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer","volume":"238","author":"Zagon IS","year":"2013","unstructured":"Zagon IS, Donahue R, McLaughlin PJ. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood). 2013, 238:579-87. 10.1177\/1535370213488483","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1124\/pr.110.004135","article-title":"Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia","volume":"63","author":"Hutchinson MR","year":"2011","unstructured":"Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011, 63:772-810. 10.1124\/pr.110.004135","journal-title":"Pharmacol Rev"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00075.2009","article-title":"Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis","volume":"296","author":"Donahue RN","year":"2009","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol. 2009, 296:R1716-25. 10.1152\/ajpregu.00075.2009","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3390\/medsci6040082","article-title":"Low-dose naltrexone (LDN)-review of therapeutic utilization","volume":"6","author":"Toljan K","year":"2018","unstructured":"Toljan K, Vrooman B. Low-dose naltrexone (LDN)-review of therapeutic utilization. Med Sci (Basel). 2018, 6:82. 10.3390\/medsci6040082","journal-title":"Med Sci (Basel)"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono C","year":"2005","unstructured":"Patrono C, Garc\u00eda Rodr\u00edguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005, 353:2373-83. 10.1056\/NEJMra052717","journal-title":"N Engl J Med"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay LJ","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011, 11:123-34. 10.1038\/nrc3004","journal-title":"Nat Rev Cancer"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang D","year":"2010","unstructured":"Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010, 10:181-93. 10.1038\/nrc2809","journal-title":"Nat Rev Cancer"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"377","author":"Rothwell PM","year":"2011","unstructured":"Rothwell PM, Fowkes FG, Belch JF, et al.. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2011, 377:31-41. 10.1016\/S0140-6736(10)61543-7","journal-title":"Lancet"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30366-4","article-title":"Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial","volume":"395","author":"Burn J","year":"2020","unstructured":"Burn J, Sheth H, Elliott F, et al.. Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020, 395:1855-63. 10.1016\/S0140-6736(20)30366-4","journal-title":"Lancet"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12131","article-title":"Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers","volume":"169","author":"Aggarwal BB","year":"2013","unstructured":"Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013, 169:1672-92. 10.1111\/bph.12131","journal-title":"Br J Pharmacol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2008.03.025","article-title":"Curcumin and cancer: an \"old-age\" disease with an \"age-old\" solution","volume":"267","author":"Anand P","year":"2008","unstructured":"Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an \"old-age\" disease with an \"age-old\" solution. Cancer Lett. 2008, 267:133-64. 10.1016\/j.canlet.2008.03.025","journal-title":"Cancer Lett"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22179","article-title":"Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice","volume":"54","author":"Li W","year":"2015","unstructured":"Li W, Hua B, Saud SM, et al.. Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol Carcinog. 2015, 54:1096-109. 10.1002\/mc.22179","journal-title":"Mol Carcinog"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27144523","article-title":"Anticancer effects and mechanisms of berberine from medicinal herbs: an update review","volume":"27","author":"Xiong RG","year":"2022","unstructured":"Xiong RG, Huang SY, Wu SX, et al.. Anticancer effects and mechanisms of berberine from medicinal herbs: an update review. Molecules. 2022, 27:10.3390\/molecules27144523","journal-title":"Molecules"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.09.029","article-title":"Thymoquinone: potential cure for inflammatory disorders and cancer","volume":"83","author":"Woo CC","year":"2012","unstructured":"Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 2012, 83:443-51. 10.1016\/j.bcp.2011.09.029","journal-title":"Biochem Pharmacol"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2005.06.008","article-title":"Immunomodulatory and therapeutic properties of the Nigella sativa L. seed","volume":"5","author":"Salem ML","year":"2005","unstructured":"Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol. 2005, 5:1749-70. 10.1016\/j.intimp.2005.06.008","journal-title":"Int Immunopharmacol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1080\/01635580802582777","article-title":"Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies","volume":"61","author":"Calviello G","year":"2009","unstructured":"Calviello G, Serini S, Piccioni E, Pessina G. Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr Cancer. 2009, 61:287-301. 10.1080\/01635580802582777","journal-title":"Nutr Cancer"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0b013e32835d2d99","article-title":"Omega-3 fatty acids in cancer","volume":"16","author":"Laviano A","year":"2013","unstructured":"Laviano A, Rianda S, Molfino A, Rossi Fanelli F. Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care. 2013, 16:156-61. 10.1097\/MCO.0b013e32835d2d99","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2008.08.038","article-title":"Modified citrus pectin anti-metastatic properties: one bullet, multiple targets","volume":"344","author":"Glinsky VV","year":"2009","unstructured":"Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009, 344:1788-91. 10.1016\/j.carres.2008.08.038","journal-title":"Carbohydr Res"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1038\/sj.pcan.4500679","article-title":"Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study","volume":"6","author":"Guess BW","year":"2003","unstructured":"Guess BW, Scholz MC, Strum SB, Lam RY, Johnson HJ, Jennrich RI. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis. 2003, 6:301-4. 10.1038\/sj.pcan.4500679","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1615\/IntJMedMushr.v12.i1.10","article-title":"Medicinal mushroom science: history, current status, future trends, and unsolved problems","volume":"12","author":"Wasser SP","year":"2010","unstructured":"Wasser SP. Medicinal mushroom science: history, current status, future trends, and unsolved problems. Int J Med Mushrooms. 2010, 12:1-16. 10.1615\/IntJMedMushr.v12.i1.10","journal-title":"Int J Med Mushrooms"},{"key":"ref97","article-title":"The use of mushroom glucans and proteoglycans in cancer treatment","volume":"5","author":"Kidd PM","year":"2000","unstructured":"Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000, 5:4-27.","journal-title":"Altern Med Rev"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-2-2","article-title":"Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases","volume":"2","author":"Kell DB","year":"2009","unstructured":"Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics. 2009, 2:2. 10.1186\/1755-8794-2-2","journal-title":"BMC Med Genomics"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1111\/nure.12155","article-title":"Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy","volume":"72","author":"Zhang Y","year":"2014","unstructured":"Zhang Y, Lima CF, Rodrigues LR. Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy. Nutr Rev. 2014, 72:763-73. 10.1111\/nure.12155","journal-title":"Nutr Rev"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/88.2.565S","article-title":"Vitamin D and cancer: current dilemmas and future research needs","volume":"88","author":"Davis CD","year":"2008","unstructured":"Davis CD. Vitamin D and cancer: current dilemmas and future research needs. Am J Clin Nutr. 2008, 88:565S-9S. 10.1093\/ajcn\/88.2.565S","journal-title":"Am J Clin Nutr"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2196","article-title":"Vitamin D signalling pathways in cancer: potential for anticancer therapeutics","volume":"7","author":"Deeb KK","year":"2007","unstructured":"Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007, 7:684-700. 10.1038\/nrc2196","journal-title":"Nat Rev Cancer"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.2119\/2008-00033.Prasad","article-title":"Zinc in human health: effect of zinc on immune cells","volume":"14","author":"Prasad AS","year":"2008","unstructured":"Prasad AS. Zinc in human health: effect of zinc on immune cells. Mol Med. 2008, 14:353-7. 10.2119\/2008-00033.Prasad","journal-title":"Mol Med"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2007.02.033","article-title":"Zinc as an anti-tumor agent in prostate cancer and in other cancers","volume":"463","author":"Franklin RB","year":"2007","unstructured":"Franklin RB, Costello LC. Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys. 2007, 463:211-7. 10.1016\/j.abb.2007.02.033","journal-title":"Arch Biochem Biophys"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61452-9","article-title":"Selenium and human health","volume":"379","author":"Rayman MP","year":"2012","unstructured":"Rayman MP. Selenium and human health. Lancet. 2012, 379:1256-68. 10.1016\/S0140-6736(11)61452-9","journal-title":"Lancet"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.1.86","article-title":"Magnesium intake in relation to risk of colorectal cancer in women","volume":"293","author":"Larsson SC","year":"2005","unstructured":"Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA. 2005, 293:86-9. 10.1001\/jama.293.1.86","journal-title":"JAMA"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04298.x","article-title":"Cannabidiol as potential anticancer drug","volume":"75","author":"Massi P","year":"2013","unstructured":"Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013, 75:303-12. 10.1111\/j.1365-2125.2012.04298.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0688","article-title":"A combined preclinical therapy of cannabinoids and temozolomide against glioma","volume":"10","author":"Torres S","year":"2011","unstructured":"Torres S, Lorente M, Rodr\u00edguez-Forn\u00e9s F, et al.. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011, 10:90-103. 10.1158\/1535-7163.MCT-10-0688","journal-title":"Mol Cancer Ther"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5575","article-title":"Bicarbonate increases tumor pH and inhibits spontaneous metastases","volume":"69","author":"Robey IF","year":"2009","unstructured":"Robey IF, Baggett BK, Kirkpatrick ND, et al.. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009, 69:2260-8. 10.1158\/0008-5472.CAN-07-5575","journal-title":"Cancer Res"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-012-0233-x","article-title":"Hyperbaric oxygen therapy and cancer--a review","volume":"7","author":"Moen I","year":"2012","unstructured":"Moen I, Stuhr LE. Hyperbaric oxygen therapy and cancer--a review. Target Oncol. 2012, 7:233-42. 10.1007\/s11523-012-0233-x","journal-title":"Target Oncol"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1111\/sms.12581","article-title":"Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases","volume":"25 Suppl 3","author":"Pedersen BK","year":"2015","unstructured":"Pedersen BK, Saltin B. Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015, 25 Suppl 3:1-72. 10.1111\/sms.12581","journal-title":"Scand J Med Sci Sports"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu012","article-title":"Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis","volume":"25","author":"Schmid D","year":"2014","unstructured":"Schmid D, Leitzmann MF. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014, 25:1293-311. 10.1093\/annonc\/mdu012","journal-title":"Ann Oncol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2747","article-title":"Metabolism and cancer: the circadian clock connection","volume":"9","author":"Sahar S","year":"2009","unstructured":"Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009, 9:886-96. 10.1038\/nrc2747","journal-title":"Nat Rev Cancer"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1820","article-title":"The influence of bio-behavioural factors on tumour biology: pathways and mechanisms","volume":"6","author":"Antoni MH","year":"2006","unstructured":"Antoni MH, Lutgendorf SK, Cole SW, et al.. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006, 6:240-8. 10.1038\/nrc1820","journal-title":"Nat Rev Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/474404-targeted-metabolic-therapy-in-cancer-a-comprehensive-metabolic-treatment-strategy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:44:48Z","timestamp":1778089488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/474404-targeted-metabolic-therapy-in-cancer-a-comprehensive-metabolic-treatment-strategy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":113,"URL":"https:\/\/doi.org\/10.7759\/cureus.108373","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,6]]}}}